Netherlands· NL-e53ef3ea2377
Reblozyl 75 mg, poeder voor oplossing voor injectie
A luspatercept product containing luspatercept, registered in Netherlands by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Luspatercept is registered in 14 of 19 countries.
Countries holding a registration under ATC B03XA06 (luspatercept), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Luspatercept · ATC B03XA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- LUSPATERCEPT
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Netherlands (NL)
- ATC code
- B03XA06
- ATC class
- Luspatercept
- Defined daily dose
- 3.33 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/20/1452
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Luspatercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceREBLOZYL 75 mg, poudre pour solution injectableBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- IrelandReblozyl 75 mg powder for solution for injectionBristol-Myers Squibb Pharma EEIG
- United StatesReblozylCelgene Corporation
- CanadaREBLOZYLBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandReblozyl 25 mg, Pulver zur Herstellung einer InjektionslösungBristol-Myers Squibb SA
- CzechiaREBLOZYLBristol-Myers Squibb Pharma EEIG, Dublin
- SpainREBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLEBristol-Myers Squibb Pharma Eeig
- FinlandReblozylBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Reblozyl
- Liechtenstein · Reblozyl
- Norway · Reblozyl
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f53ba4da-b2ea-476b-a89a-7758c7c907de GET /v1/drugs/f53ba4da-b2ea-476b-a89a-7758c7c907de?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/reblozyl-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Luspatercept",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp124955",
"excipients": [
"CITROENZUUR 1-WATER (E 330)",
"NATRIUMHYDROXIDE (E 524)",
"POLYSORBAAT 80 (E 433)",
"SACCHAROSE",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"ZOUTZUUR (E 507)"
],
"substances": [
"LUSPATERCEPT"
],
"leaflet_url": null,
"authorised_at": "2020/06/25",
"procedure_number": "EMEA/H/C/004444",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/20/1452",
"additional_monitoring": "N"
}See everything about luspatercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.